Skip to main content
. 2023 Nov 20;271(2):699–710. doi: 10.1007/s00415-023-12084-4

Fig. 1.

Fig. 1

Flowchart of patients selection and analysis. N number, OCR Ocrelizumab, MS Multiple Sclerosis, PRE-LOCK cycle OCR infusion interval before the observation period, LOCK cycle OCR infusion interval during the observation period, SID standard interval dosing, EID extended interval dosing, RRMS relapsing remitting MS